Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pressure Mounts For Amylin As Bydureon PDUFA Approaches

This article was originally published in The Pink Sheet Daily

Executive Summary

With declining sales of Byetta, Amylin has staked its near-term future on the performance of Bydureon, a long-acting formulation of the active ingredient in Byetta.

Advertisement

Related Content

Amylin’s Bydureon Approval: How Does It Sit With Novo Nordisk?
With Lilly Out, Amylin’s Future Is Tied To Bydureon
Amylin's Once-Weekly Bydureon Clears Major Cardiac Safety Hurdle
Sanofi/Zealand Release Head-To-Head Data For Lixisenatide Vs. Exenatide
Roche/Ipsen's Suspended Taspoglutide Could Become Another Diabetes Casualty

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS073298

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel